S. Sait and S. Modak, "Anti-GD2 immunotherapy for neuro- blastoma," Expert Review of Anticancer Therapy, vol. 17, no. 10, pp. 889-904, 2017.Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert Rev Anticancer Ther. 2017;17(10):889-904....
“The sponsor has provided sufficient information to show that chimeric monoclonal antibody to O-acetyl-GD2 antigen might be of significant benefit for patients with neuroblastoma because it works in a different way to currently authorised treatments by specifically targeting tumour tissue. In addition, ...
Anti-CD105 antibody eliminates tumor microenvironment cells and enhances anti-GD2 antibody immunotherapy of neuroblastoma with activated natural killer cells. Clin. Cancer Res. 25, 4761–4774 (2019). Article CAS PubMed PubMed Central Google Scholar George, J. et al. Comprehensive genomic profiles ...
and L.S.M are co-inventors on pending patent applications that relate to the use of NKT cells in cancer immunotherapy and have been licensed by Baylor College of Medicine to Kuur Therapeutics for commercial development. Kuur Therapeutics provided research support for this project (to L.S.M.) ...
CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review 2022, Biomedicines Show abstract Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off-the-shelf versatile tumor delivery vehicle 2024, Medicinal...
There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was ...
Anti-GD2 immunotherapy improves survival but not all responses are durable. Transforming growth factor-beta (TGFβ) has been implicated in solid tumor immunoresistance. High-risk NBs harbor activated MYC or MYCN to coordinately expand intratumoral polyamines (PA), oncometabolites with immunomodulatory ...
A substantial body of clinical data support the immunotherapy combination of anti‐GD2 monoclonal antibodies and GM‐CSF. In contrast, clinical data supporting the use of G‐CSF are limited. No formal comparison between GM‐CSF, G‐CSF and no cytokine has been identified. The treatment...
et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase 1 clinical trial. Clin. Cancer Res. 23, 3510–3519 (2017). Article CAS PubMed PubMed Central Google Scholar Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory...
The observed trogocytosis may represent a novel mechanism of resistance to immunotherapy in neuroblastoma.Abigail K. ZamoraMichael J. ZobelJianping SunMichael SheardRobert SeegerEugene S. KimPediatrics